Protective Role of Estrogen-induced MiRNA-29 Expression in Carbon Tetrachloride-induced Mouse Liver Injury
Overview
Authors
Affiliations
Previous studies have indicated that female animals are more resistant to carbon tetrachloride (CCl(4))-induced liver fibrosis than male animals, and that estradiol (E(2)) treatment can inhibit CCl(4)-induced animal hepatic fibrosis. The underlying mechanism governing these phenomena, however, has not been fully elucidated. Here we reported the role of estrogen-induced miRNA-29 (miR-29) expression in CCl(4)-induced mouse liver injury. Hepatic miR-29 levels were differentially regulated in female and male mice during CCl(4) treatment. Specifically, the levels of miR-29a and miR-29b expression were significantly decreased in the livers of male, but not female, mice following 4 weeks of CCl(4) treatment. The down-regulation of miR-29a and miR-29b in male mouse livers correlated with the early development of liver fibrosis, as indicated by increased expressions of fibrotic markers in male mice relative to female mice. In addition, E(2) was maintained at a higher level in female mice than in male mice. In contrast to TGF-β1 that decreased miR-29a/b expression in murine hepatoma IAR20 cells and normal hepatocytes, E(2) enhanced the expression of miR-29a/b through suppression of the nuclear factor-κB (NF-κB) signal pathway, which negatively regulates miR-29 expression. Furthermore, both E(2) treatment and intravenous injection of the recombinant adenovirus expressing miR-29a/b markedly increased the miR-29a/b level and attenuated the expression of fibrotic markers in mouse livers during CCl(4) treatment, supporting the protective role of E(2)-induced miR-29 in CCl(4)-induced hepatic injury. In conclusion, our results collectively demonstrate that estrogen can inhibit CCl(4)-induced hepatic injury through the induction of hepatic miR-29.
Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies.
Sadri M, Shafaghat Z, Roozbehani M, Hoseinzadeh A, Mohammadi F, Arab F Probiotics Antimicrob Proteins. 2024; .
PMID: 39739162 DOI: 10.1007/s12602-024-10431-z.
Samuvel D, Lemasters J, Chou C, Zhong Z Front Pharmacol. 2024; 15:1386238.
PMID: 38828459 PMC: 11140137. DOI: 10.3389/fphar.2024.1386238.
Rajabi S, Saberi S, Najafipour H, Askaripour M, Rajizadeh M, Shahraki S Mol Biol Rep. 2024; 51(1):137.
PMID: 38236310 DOI: 10.1007/s11033-023-09127-4.
Zhu N, Song Y, Zhang C, Wang K, Han J Front Med (Lausanne). 2023; 10:1294425.
PMID: 38020132 PMC: 10657835. DOI: 10.3389/fmed.2023.1294425.
Sex differences in chronic liver disease and benign liver lesions.
Cooper K, Delk M, Devuni D, Sarkar M JHEP Rep. 2023; 5(11):100870.
PMID: 37791378 PMC: 10542645. DOI: 10.1016/j.jhepr.2023.100870.